Fabio Luis Souza Duran

Fabio Luis Souza Duran

Auto-generated profile, based on publicly available information

Fabio Luis Souza Duran

Laboratory of Psychiatric Neuroimaging (LIM-21), Departamento e Instituto de Psiquiatria, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2017 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
DHD P Hibar
D P Hibar
LWL T Westlye
L T Westlye
NDN T Doan
N T Doan
NJN Jahanshad
N Jahanshad
JCJ W Cheung
J W Cheung
OAO A Andreassen
O A Andreassen
Despite decades of research, the pathophysiology of bipolar disorder (BD) is still not well understood. Structural brain differences have been associated with BD, but results from neuroimaging studies have been inconsistent. To address this, we performed the largest study to date of cortical gray matter thickness and surface area measures from brain magnetic resonance imaging scans of 6503 individuals including 1837 unrelated adults with BD and 2582 unrelated healthy controls for group differences while also examining the effects of commonly prescribed medications, age of illness onset, history of psychosis, mood state, age and sex differences on cortical regions. In BD, cortical gray matter was thinner in frontal, temporal and parietal regions of both brain hemispheres. BD had the strongest effects on left pars opercularis (Cohen’s d=−0.293; P=1.71 × 10−21), left fusiform gyrus (d=−0.288; P=8.25 × 10−21) and left rostral middle frontal cortex (d=−0.276; P=2.99 × 10−19). Longer duration of illness (after accounting for age at the time of scanning) was associated with reduced cortical thickness in frontal, medial parietal and occipital regions. We found that several commonly prescribed medications, including lithium, antiepileptic and antipsychotic treatment showed significant associations with cortical thickness and surface area, even after accounting for patients who received multiple medications. We found evidence of reduced cortical surface area associated with a history of psychosis but no associations with mood state at the time of scanning. Our analysis revealed previously undetected associations and provides an extensive analysis of potential confounding variables in neuroimaging studies of BD.

1 April 2018 in American Journal of Psychiatry
Verified
Journal Article
Closed access
DRDaan van Rooij
Daan van Rooij
EAEvdokia Anagnostou
Evdokia Anagnostou
CACelso Arango
Celso Arango
GAGuillaume Auzias
Guillaume Auzias
MBMarlene Behrmann
Marlene Behrmann
JBJan K. Buitelaar
Jan K. Buitelaar

9 September 2010 in Journal of Psychopharmacology
Verified
Journal Article
Open access
PDF file
JCJOSE A DE S de Souza CRIPPA
JOSE A DE S de Souza CRIPPA
GDGuilherme Nogueira Derenusson
Guilherme Nogueira Derenusson
TFThiago Borduqui Ferrari
Thiago Borduqui Ferrari
LWLauro Wichert-Ana
Lauro Wichert-Ana
FDFábio Ls Duran
Fábio Ls Duran
JHJaime Eduardo Cecílio Hallak
Jaime Eduardo Cecílio Hallak
Animal and human studies indicate that cannabidiol (CBD), a major constituent of cannabis, has anxiolytic properties. However, no study to date has investigated the effects of this compound on human pathological anxiety and its underlying brain mechanisms. The aim of the present study was to investigate this in patients with generalized social anxiety disorder (SAD) using functional neuroimaging. Regional cerebral blood flow (rCBF) at rest was measured twice using (99m)Tc-ECD SPECT in 10 treatment-naïve patients with SAD. In the first session, subjects were given an oral dose of CBD (400 mg) or placebo, in a double-blind procedure. In the second session, the same procedure was performed using the drug that had not been administered in the previous session. Within-subject between-condition rCBF comparisons were performed using statistical parametric mapping. Relative to placebo, CBD was associated with significantly decreased subjective anxiety (p < 0.001), reduced ECD uptake in the left parahippocampal gyrus, hippocampus, and inferior temporal gyrus (p < 0.001, uncorrected), and increased ECD uptake in the right posterior cingulate gyrus (p < 0.001, uncorrected). These results suggest that CBD reduces anxiety in SAD and that this is related to its effects on activity in limbic and paralimbic brain areas.

18 May 2020 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
LHLaura K. M. Han
Laura K. M. Han
RDRichard Dinga
Richard Dinga
THTim Hahn
Tim Hahn
CCChristopher R. K. Ching
Christopher R. K. Ching
LELisa T Eyler
Lisa T Eyler
LSLianne Schmaal
Lianne Schmaal
Major depressive disorder (MDD) is associated with an increased risk of brain atrophy, aging-related diseases, and mortality. We examined potential advanced brain aging in adult MDD patients, and whether this process is associated with clinical characteristics in a large multicenter international dataset. We performed a mega-analysis by pooling brain measures derived from T1-weighted MRI scans from 19 samples worldwide. Healthy brain aging was estimated by predicting chronological age (18–75 years) from 7 subcortical volumes, 34 cortical thickness and 34 surface area, lateral ventricles and total intracranial volume measures separately in 952 male and 1236 female controls from the ENIGMA MDD working group. The learned model coefficients were applied to 927 male controls and 986 depressed males, and 1199 female controls and 1689 depressed females to obtain independent unbiased brain-based age predictions. The difference between predicted “brain age” and chronological age was calculated to indicate brain-predicted age difference (brain-PAD). On average, MDD patients showed a higher brain-PAD of +1.08 (SE 0.22) years (Cohen’s d = 0.14, 95% CI: 0.08–0.20) compared with controls. However, this difference did not seem to be driven by specific clinical characteristics (recurrent status, remission status, antidepressant medication use, age of onset, or symptom severity). This highly powered collaborative effort showed subtle patterns of age-related structural brain abnormalities in MDD. Substantial within-group variance and overlap between groups were observed. Longitudinal studies of MDD and somatic health outcomes are needed to further assess the clinical value of these brain-PAD estimates.

31 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMerel C. Postema
Merel C. Postema
DRDaan van Rooij
Daan van Rooij
EAEvdokia Anagnostou
Evdokia Anagnostou
CACelso Arango
Celso Arango
GAGuillaume Auzias
Guillaume Auzias
CFClyde Francks
Clyde Francks
Altered structural brain asymmetry in autism spectrum disorder (ASD) has been reported. However, findings have been inconsistent, likely due to limited sample sizes. Here we investigated 1,774 individuals with ASD and 1,809 controls, from 54 independent data sets of the ENIGMA consortium. ASD was significantly associated with alterations of cortical thickness asymmetry in mostly medial frontal, orbitofrontal, cingulate and inferior temporal areas, and also with asymmetry of orbitofrontal surface area. These differences generally involved reduced asymmetry in individuals with ASD compared to controls. Furthermore, putamen volume asymmetry was significantly increased in ASD. The largest case-control effect size was Cohen’sd = −0.13, for asymmetry of superior frontal cortical thickness. Most effects did not depend on age, sex, IQ, severity or medication use. Altered lateralized neurodevelopment may therefore be a feature of ASD, affecting widespread brain regions with diverse functions. Large-scale analysis was necessary to quantify subtle alterations of brain structural asymmetry in ASD.

1 September 2005 in Biological Psychiatry
Verified
Journal Article
Closed access
AVAntonio A. Valente
Antonio A. Valente
EMEuripedes C. Miguel
Euripedes C. Miguel
CCClaudio C. Castro
Claudio C. Castro
EAEdson Amaro
Edson Amaro
FDFabio L.S. Duran
Fabio L.S. Duran
GBGeraldo F. Busatto
Geraldo F. Busatto